Abstracts tagged "psoriasis"

Abstract Number: 1422 • 2016 ACR/ARHP Annual Meeting
Identifying Generic and Specific Patients’ Perspectives on Disease- and Treatment-Related Issues in Rheumatoid Arthritis, Psoriatic Arthritis, and Psoriasis: A Qualitative Concept Mapping Study
Tanja Schjødt Jørgensen¹, Louise Klokker¹, Henrik Gudbergsen², Simon Francis Thomsen³, Robin Christensen⁴, Henning Bliddal¹ and Lars Erik Kristensen¹, ¹The Parker Institute, Copenhagen University Hospital, Bispebjerg and Frederiksberg, Copenhagen, Denmark, ²The Parker Institute, Copenhagen University Hospital, Bispebjerg and Frederiksberg,, Copenhagen, Denmark, ³Department of Dermatology, Bispebjerg Hospital & Department of Biomedical Sciences, University of Copenhagen, Copenhagen, Denmark, ⁴Musculoskeletal Statistics Unit, The Parker Institute, Copenhagen University Hospital, Bispebjerg and Frederiksberg, Copenhagen, Denmark
Identifying generic and specific patients’ perspectives on disease- and treatment-related issues in rheumatoid arthritis, psoriatic arthritis, and psoriasis: a qualitative concept mapping studyT.S. Jørgensen1, L.…
Abstract Number: 7L • 2015 ACR/ARHP Annual Meeting
Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA): Treatment Recommendations for Psoriatic Arthritis 2015
Laura C Coates^1,2, Arthur Kavanaugh³, Philip J. Mease⁴, Enrique R. Soriano⁵, M Laura Acosta-Felquer⁶, April W Armstrong⁷, Wilson Bautista-Molano⁸, Wolf-Henning Boehncke⁹, Willemina Campbell¹⁰, Alberto Cauli¹¹, Luis Espinoza¹², Oliver FitzGerald¹³, Dafna D. Gladman¹⁴, Alice B. Gottlieb¹⁵, Philip S. Helliwell², M. Elaine Husni¹⁶, Thorvardur Love^17,18, Ennio Lubrano¹⁹, Neil J McHugh²⁰, Peter Nash²¹, Alexis Ogdie-Beatty²², Ana-Maria Orbai²³, Andrew Parkinson²⁴, Denis O'Sullivan²⁵, Cheryl F Rosen²⁶, Sergio Schwartzman²⁷, Evan Siegel²⁸, Sergio Toloza²⁹, William Tuong³⁰ and Christopher T. Ritchlin³¹, ¹Medicine, University of Rochester, Rochester, NY, ²Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, ³University of California San Diego, La Jolla, CA, ⁴Rheumatology Research, Swedish Medical Center, Seattle, WA, ⁵Rheumatology, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, ⁶Rheumatology Unit, Internal Medicine Service, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, ⁷Keck School of Medicine, University of Southern California, Los Angeles, CA, ⁸Department of Rheumatology, Faculty of Medicine HMC/UMNG, Bogota, Colombia, Bogotá, Colombia, ⁹Department of Dermatology,, Geneva University Hospital, Geneva, Switzerland, ¹⁰Toronto Western Hospital, Toronto, ON, Canada, ¹¹University of Cagliari, Cagliari, Italy, ¹²Medicine-Section of Rheumatology, LSU Medical Center, New Orleans, LA, ¹³Department of Rheumatology, St. Vincent’s University Hospital, UCD School of Medicine and Medical Sciences and Conway Institute of Biomolecular and Biomedical Research, University College Dublin, Dublin, Ireland, ¹⁴Division of Rheumatology, Toronto Western Hospital and University of Toronto, Toronto, ON, Canada, ¹⁵Tufts Medical Center, Boston, MA, ¹⁶Rheumatology Dept A50, Cleveland Clinic, Cleveland, OH, ¹⁷Faculty of Medicine, University of Iceland, Reykjavik, Iceland, ¹⁸Landspitali University Hospital, Reykjavík, Iceland, ¹⁹Cattedra di Reumatologia, Università del Molise, Campobasso, Italy, ²⁰Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom, ²¹Department of Medicine, University of Queensland, Brisbane, Australia, ²²Medicine/Rheumatology, Epidemiology and Biostatistics, University of Pennsylvania, Philadelphia, PA, ²³Rheumatology, Johns Hopkins University, Baltimore, MD, ²⁴Chapel Allerton Hospital, Leeds, United Kingdom, ²⁵St. Vincent’s University Hospital, Dublin, Ireland, ²⁶Division of Dermatology, Toronto Western Hospital, University of Toronto, Toronto, ON, Canada, ²⁷Rheumatology, Hospital for Special Surgery, New York, NY, ²⁸Arthritis & Rheumatism Assoc, Wheaton, MD, ²⁹Rheumatology, Ministry of Health, San Fernando del Valle de Catamarca, Argentina, ³⁰Department of Dermatology, University of California David, Davis, CA, ³¹Allergy, Immunology and Rheumatololgy Division, University of Rochester Medical Center, Rochester, NY
Background/Purpose: Since the 2009 GRAPPA treatment recommendations were published, therapeutic options and management strategies for psoriatic arthritis (PsA) have advanced considerably. We updated and improved…
Abstract Number: 1737 • 2015 ACR/ARHP Annual Meeting
Increased Osteoclast Precursors with an Elevated DC-STAMP Expression May Identify Psoriasis Patients at Risk for Psoriatic Arthritis
Yahui Grace Chiu¹, Sutha Shanmugarajah², Dongge Li³, Megan Freiburger⁴, Sharon Moorehead⁵, Dafna Gladman⁶ and Christopher T. Ritchlin⁷, ¹Allergy, Immunology, and Rheumatology, University of Rochester, Rochester, NY, ²Toronto Western Hospital, Toronto, ON, Canada, ³Allergy, Immunology and Rheumatology, University of Rochester, Rochester, NY, ⁴Biology, University of Rochester, Rochester, NY, ⁵Allergy, Immunology & Rheumatology, University of Rochester, Rochester, NY, ⁶Allergy, Immunology & Rheumatology, Toronto Western Hospital, Toronto, ON, Canada, ⁷Allergy, Immunology and Rheumatololgy Division, University of Rochester Medical Center, Rochester, NY
Background/Purpose: Approximately 25% of psoriasis (Ps) patients develop into psoriatic arthritis (PsA) within 10 years. This Ps-to-PsA transition paradigm provides a unique opportunity to recognize…
Abstract Number: 2063 • 2015 ACR/ARHP Annual Meeting
The Survival Impact of Statins in Psoriasis and Psoriatic Arthritis: A General Population-Based Cohort Study
Sian Yik Lim¹, Na Lu² and Hyon K. Choi², ¹Division of Rheumatology, Allergy and Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, ²Rheumatology, Allergy and Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, MA
Background/Purpose: Given their lipid-lowering and anti-inflammatory properties, statins may have dual cardioprotective and anti-rheumatic benefits in psoriasis or psoriatic arthritis. These effects may confer survival…
Abstract Number: 2065 • 2015 ACR/ARHP Annual Meeting
Verification of Novel Soluble Biomarkers That Differentiate Patients with Psoriatic Arthritis from Those with Psoriasis without Psoriatic Arthritis
Vinod Chandran¹, Daniela Cretu^2,3, Lisa Gao⁴, Kun Liang⁴, Antoninus Soosaipillai³ and Eleftherios Diamandis^2,3,5, ¹Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ²Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, Canada, ³Department of Pathology and Laboratory Medicine, Mount Sinai Hospital, Toronto, ON, Canada, ⁴Department of Statistics and Actuarial Science, University of Waterloo, Waterloo, ON, Canada, ⁵Department of Clinical Biochemistry, University Health Network, Toronto, ON, Canada
Background/Purpose: There is a high prevalence of undiagnosed psoriatic arthritis (PsA) in psoriasis patients. Therefore identifying soluble biomarkers for PsA will help in screening psoriasis…
Abstract Number: 2806 • 2015 ACR/ARHP Annual Meeting
Bacterial Skin Microbiome in Psoriatic Arthritis Ã¢â‚¬â€œ Pilot Data from Psoriatic Plaques on Dry Skin Sites from Patients with Psoriasis (PsC) and Psoriatic Arthritis (PsA)
Madhura Castelino¹, Stephen Eyre², Mauro Tutino², John Moat³, Paul Martin², Umer Ijaz⁴, Christopher Quince⁵, Pauline Ho¹, Mathew Upton⁶ and Anne Barton^1,7, ¹NIHR Manchester Musculoskeletal Biomedical Research Unit, Manchester Academic Health Science Centre, Manchester, United Kingdom, ²Arthritis Research UK Centre for Genetics and Genomics, University of Manchester, Manchester, United Kingdom, ³Microbiology and Virology Unit, University of Manchester, Manchester, United Kingdom, ⁴School of Engineering, University of Glasgow, Glasgow, United Kingdom, ⁵Warwick Medical School, University of Warwick, Coventry, United Kingdom, ⁶Plymouth University Peninsula Schools of Medicine and Dentistry, Plymouth, United Kingdom, ⁷Arthritis Research UK Centre for Genetics and Genomics, Centre for Musculoskeletal Research, Manchester Academic Health Science Centre, The University Of Manchester, Manchester, United Kingdom
Background/Purpose: In complex traits like psoriasis (PsC) and psoriatic arthritis (PsA) interactions between genetics and environmental factors are thought to result in the development of…
Abstract Number: 2886 • 2015 ACR/ARHP Annual Meeting
Secukinumab Safety and Tolerability in Patients with Active Psoriatic Arthritis and Psoriasis: Results from a Pooled Safety Analysis
Philip J. Mease¹, Iain B. McInnes², Alice B. Gottlieb³, Albert Widmer⁴, Luminita Pricop⁵ and Shephard Mpofu⁴, ¹Rheumatology Research, Swedish Medical Center, Seattle, WA, ²Immunology, Infection and Inflammation, University of Glasgow, Glasgow, United Kingdom, ³Dermatology, Tufts Medical Center, Boston, MA, ⁴Novartis Pharma AG, Basel, Switzerland, ⁵Integrated Hospital Care (IHC) Franchise, Novartis Pharmaceuticals Corporation, East Hanover, NJ
Background/Purpose: Secukinumab, a fully human anti–interleukin-17A monoclonal antibody, has been shown to improve the signs and symptoms of psoriasis and psoriatic arthritis (PsA).1–3 Here, we…
Abstract Number: 3118 • 2015 ACR/ARHP Annual Meeting
Clinical Characteristics and Disease Outcomes in Psoriatic Arthritis Patients By Extent of Body Surface Area Affected By Psoriasis: Results from Corrona Registry
Philip J. Mease^1,2,3,4, Chitra Karki⁵, Carol J. Etzel^5,6, Arthur Kavanaugh⁷, Christopher T. Ritchlin⁸, Wendi Malley⁵, Vivian Herrera⁹, Jacqueline B. Palmer⁹ and Jeffrey D. Greenberg^5,10, ¹Swedish Medical Center and University of Washington School of Medicine, Seattle, WA, ²Seattle Rheumatology Associates, Seattle, WA, ³Rheumatology Research, Swedish Medical Center, Seattle, WA, ⁴Clinical Professor, University of Washington School of Medicine, Seattle, WA, ⁵Corrona, LLC, Southborough, MA, ⁶University of Texas M.D. Anderson Cancer Center, Houston, TX, ⁷University of California San Diego, La Jolla, CA, ⁸Allergy, Immunology and Rheumatololgy Division, University of Rochester Medical Center, Rochester, NY, ⁹Novartis Pharmaceuticals Corporation, East Hanover, NJ, ¹⁰NYU School of Medicine, New York, NY
Background/Purpose: Psoriatic arthritis (PsA) is a type of inflammatory arthritis that is commonly comorbid with the skin condition, psoriasis. A major contributor to the severity…
Abstract Number: 3119 • 2015 ACR/ARHP Annual Meeting
The Risk of Venous Thromboembolism in Psoriatic Arthritis, Psoriasis and Rheumatoid Arthritis
Alexis Ogdie-Beatty¹, Daniel Shin², Junko Takeshita², Zelma ChiesaFuxench² and Joel Gelfand³, ¹Medicine/Rheumatology, University of Pennsylvania, Philadelphia, PA, ²University of Pennsylvania, Philadelphia, PA, ³University of Pennsylvania Health System , Philadelphia, PA
Background/Purpose: Venous thromboembolism (VTE), the combined endpoint of deep venous thrombosis (DVT) and pulmonary embolism (PE), is a common and potentially deadly medical problem with…
Abstract Number: 3120 • 2015 ACR/ARHP Annual Meeting
The Prevalence, Incidence and Management of Hypertension, Diabetes and Hyperlipidemia in Psoriatic Arthritis, Psoriasis and Rheumatoid Arthritis
Kashif Jafri¹, Christie M. Bartels², Daniel Shin³ and Alexis Ogdie-Beatty⁴, ¹Department of Medicine, University of Pennsylvania, Philadelphia, PA, ²Medicine, Rheumatology, University of Wisconsin School of Medicine and Public Health, Madison, WI, ³University of Pennsylvania, Philadelphia, PA, ⁴Medicine/Rheumatology, University of Pennsylvania, Philadelphia, PA
Background/Purpose: Psoriasis, psoriatic arthritis (PsA), and rheumatoid arthritis (RA) are associated with an increased risk for cardiovascular disease (CVD). While management of traditional CVD risk…
Abstract Number: 566 • 2015 ACR/ARHP Annual Meeting
Genome-Wide Trans-Ancestry Meta-Analysis of Herpes Zoster in RA and Pso Patients Treated with Tofacitinib
Nan Bing¹, HuanYu Zhou¹, BaoHong Zhang¹, John D Bradley², Makoto Nagaoka³, Hernan Valdez⁴, Michael Vincent¹ and James D. Clark¹, ¹Pfizer Inc, Cambridge, MA, ²Pfizer Inc, Groton, CT, ³Pfizer Inc, Tokyo, Japan, ⁴Pfizer Inc, New York, NY
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). Rates of herpes zoster (HZ) were higher than observed with…
Abstract Number: 3234 • 2015 ACR/ARHP Annual Meeting
Roadblocks Perceived By Canadian Dermatologists for Referring Patients with Suspected Psoriatic Arthritis
Renise Ayearst¹, Daniel Pereira¹, Charles Lynde², Holly Etchegary³ and Vinod Chandran¹, ¹Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ²University of Toronto, Toronto, ON, Canada, ³Memorial University of Newfoundland, St.John's, NF, Canada
Background/Purpose: The current system of referral by Canadian dermatologists of patients who may have psoriatic arthritis (PsA) to rheumatologists is suboptimal. Hypothesizing that knowledge level,…
Abstract Number: 649 • 2015 ACR/ARHP Annual Meeting
Measures of Health-Related Quality of Life in Psoriatic Arthritis: Are They Sensitive to Both Joint and Skin Aspects?
Mwidimi Ndosi¹, Ming-Anne Hsu², J. Cappelleri³, Amit Chhabra⁴, Heather Jones⁵ and Philip S. Helliwell⁶, ¹School of Healthcare, University of Leeds, Leeds, United Kingdom, ²445 Eastern Point Road, Pfizer Inc, Groton, CT, ³Statistics, Pfizer Inc, New London, CT, ⁴Pfizer Inc, Collegeville, PA, ⁵Inflammation Global Medical Affairs, Pfizer, Collegeville, PA, ⁶Section of Musculoskeletal Disease, University of Leeds, Leeds, United Kingdom

Background/Purpose: Psoriatic Arthritis Quality of Life (PsAQol), Ankylosing Spondylitis Quality of Life (ASQoL), and Dermatology Life Quality Index (DLQI) are tools that assess different aspects of health-related…
Abstract Number: 657 • 2015 ACR/ARHP Annual Meeting
Routine Assessment of Patient Index Data 3 Score (RAPID3) and Psoriasis Quality of Life (PQoL-12) Assess Different Domains in Psoriasis (PsO) and Psoriatic Arthritis (PsA) Patients
Kiana Vakil-Gilani¹, Alexis Dinno², Neha Garg³ and Atul A. Deodhar⁴, ¹Arthritis and Rheumatic diseases, Oregon Health and Science University, Portland, OR, ²School of Community Health, Portland State University, Portland, OR, ³Rheumatology, Oregon Health and Science University, Portland, OR, ⁴Division of Arthritis & Rheumatic Diseases, Oregon Health & Science University, Portland, OR
Background/Purpose: PQoL-12 is a validated composite tool (range: 0–120) assessing patients' quality of life in PsO and PsA. RAPID3 is another validated composite index (range:…
Abstract Number: 670 • 2015 ACR/ARHP Annual Meeting
Evaluation of the Predictive Value of Non-Specific Musculoskeletal Symptoms in Preclinical Phases of Psoriatic Arthritis
Lihi Eder¹, Ari Polachek¹, Cheryl Rosen², Vinod Chandran¹, Richard J. Cook³ and Dafna D. Gladman¹, ¹Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ²Dermatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ³Statistics and Actuarial Science, University of Waterloo, Waterloo, ON, Canada
Background/Purpose: Limited information exists about the characteristics of pre-clinical phases of psoriatic arthritis (PsA). We aimed to assess whether the presence and trends in non-specific…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].